enGene Holdings Inc. is a clinical-stage biotechnology company dedicated to the development of innovative genetic medicines, primarily targeting oncology and other serious diseases. The company's central mission is to address unmet medical needs, with a particular focus on non-muscle invasive bladder cancer (NMIBC), where current therapeutic options are limited and patient burden is high. Its lead candidate, detalimogene voraplasmid, is a non-viral gene therapy designed for patients with carcinoma in situ (CIS) who have not responded to Bacillus Calmette-Guérin (BCG) treatment.

enGene’s platforms leverage non-viral delivery mechanisms, aiming to provide localized gene therapies that transform mucosal cells into therapeutic factories, leading to potent and targeted treatment outcomes while minimizing systemic side effects. Founded in Montreal, Canada in 1999, enGene Holdings Inc. has built a reputation in the healthcare sector for advancing gene therapy beyond rare genetic conditions, aspiring to mainstream genetic medicines for broader clinical use. The company engages with healthcare professionals, researchers, and industry partners to further the commercialization and accessibility of their gene therapy innovations.